Close Menu

Cancer patients who received T cells engineered using the genome-editing technology CRISPR-Cas9 experienced no negative side effects from the treatment, according to a report in this week's Science. A team led by scientists from the University of Pennsylvania harvested T cells from three patients with refractory cancer, then used CRISPR-Cas9 to modify the cells in ways that improved their ability to target and fight tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.

Oct
28
Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Nov
11
Sponsored by
Illumina

Selective breeding represents an efficient approach to increase production of aquaculture species by means of improving traits, such as rapid growth, product quality, and disease resistance.